Ipsen in product deal with Japan's Teijin

France-based drugmaker Ipsen says that it has entered into a cross-licensing deal with Japan's Teijin which will see the latter market four of its drugs in Japan, while Ipsen will commercialize a Teijin gout product in Europe. Financial terms of the agreement were not disclosed. Under the terms of the accord, Ipsen will work to further establish Teijin's European network, with the Japanese firm doing the same for its European counterpart in the Asian market. Respective product rights will return to the companies after a solid commercial presence has been set up.